Swiss drug maker Roche has revealed that the European Commission has approved the use of Avastin for treating women with early and advanced form of ovarian cancer.
The company said that the drug has been approved for the treatment in combination with standard chemotherapy. The approval comes after two late stage studies found Avastin, when used in combination with chemotherapy, to increase the time period without the disease getting worse compared to only chemotherapy being used.
Announcing the approval, the company's Chief Medical Officer Hal Barron said, "Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years. This is the fifth tumor type for which Avastin has been approved in Europe, making it one of few biologic drugs indicated for multiple cancers."